Skip to main content
. 2012 Nov 23;41(1):175–186. doi: 10.1007/s15010-012-0367-x

Table 3.

Pre-therapy minimum inhibitory concentrations of study drugs against common pathogens (ITT with pathogens population)

N MXF (mg/L) PIP/TAZ (mg/L) AMC (mg/L)
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Staphylococcus aureus
Methicillin-susceptible 125 0.03 0.06 ≤0.015–4.0 1.0 2.0 0.5–2.0 0.50 1.0 ≤0.06–2.0
Methicillin-resistant 27 2.0 8.0 0.12–8.0 16.0 >128 4.0 to >128 8.0 >32.0 2.0 to >32.0
Enterococcus faecalis 67 0.25 16.0 0.12–16.0 4.0 8.0 2.0 to >128 1.0 1.0 0.25–32.0
Escherichia coli
Non-ESBL-producing 20 0.03 32.0 0.03 to >32.0 2.0 2.0 0.5–2.0 4.0 8.0 2.0–8.0
Bacteroides fragilis 10 0.5 2.0 0.5–4.0 0.25 0.5 0.12–1.0

ESBL extended-spectrum beta-lactamase, N total number of isolates, ITT intent-to-treat, MXF moxifloxacin, PIP/TAZ–AMC piperacillin/tazobactam–amoxicillin/clavulanic acid; Streptococcus pyogenes (n = 6): for MXF: MIC50 0.12, MIC90 0.25, range 0.12–0.25; for PIP/TAZ: MIC50 ≤0.25, MIC90 ≤0.25, range ≤0.25 to ≤0.25; for AMC: MIC50 ≤0.06, MIC90 ≤0.06, range ≤0.06 to ≤0.06; Escherichia coli ESBL-producing (n = 3): for MXF: MIC90 ≥32.0; for PIP/TAZ: MIC90 = 16.0; for AMC: MIC90 = 16.0